Clinical trial
Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
NCT04083339 is registered in ClinicalTrials.gov with Applied Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
- Lead sponsor
- Applied Therapeutics, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 20, 2019
- Completion date
- December 31, 2025
- Enrollment
- 675 (estimated)
- Sites
- 79
Conditions
As the registry lists them; a condition with its own page is linked.